New approach to treatment of recent stroke.
Ninety-one patients with acute stroke participated in a double-blind, placebo-controlled trial of naftidrofuryl. Treatment was allocated at random and given over 12 weeks, neurological and neurophysical scores being obtained before treatment and at weeks 2, 4, 8, and 12. Both treatment groups greatly improved over the 12 weeks, but the naftidrofuryl-treated patients made greater neurological progress. Of the patients eventually discharged, those given naftidrofuryl spent only half as long in hospital as the controls. Deaths attributable to stroke were significantly fewer in the active-treatment group.
D000368:Aged; D002561:Cerebrovascular Disorders / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D005663:Furans / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009257:Nafronyl / Q000627:therapeutic use*; D010351:Patient Discharge
D005663:Furans; D009257:Nafronyl